Tiziana Doses Last Alzheimer's Patient; Phase 2 Topline Data Due Q1 2027
TLSA sits 41% above its 52-week low of $0.762 on light trading volume (0.3× avg).
Summary
Tiziana dosed the last patient in its Phase 2 Alzheimer's trial of intranasal foralumab, keeping the program on track for topline data in Q1 2027. The trial tests the drug alone and with approved anti-amyloid therapies.
Key Events · Product Development and Regulatory · TLSA
-
Last Alzheimer's Patient Dosed
Final patient has begun dosing in the Phase 2 randomized, placebo-controlled trial of intranasal foralumab in early/mild Alzheimer's disease, completing enrollment and dosing initiation for all participants.
-
Topline Data Expected Q1 2027
The company anticipates announcing topline results in the first quarter of 2027; key endpoints are TSPO-PET neuroinflammation, cognitive function, and amyloid/tau fluid biomarkers.
-
Combination Arm With Approved Drugs
The trial evaluates foralumab as monotherapy and in combination with FDA-approved anti-amyloid therapies lecanemab (Leqembi) or donanemab, a positioning that could broaden its use.
-
Pipeline Momentum Continues
Follows the September 21 INFORM-MS last-visit completion, September 28 first ALS patients dosed, and September 30 FDA Orphan Drug filing for MSA, plus roughly $986,000 of CEO open-market buying in August.
Analysis · TLSA · Life Sciences
Tiziana has completed enrollment and begun dosing the final patient in its Phase 2 trial of intranasal foralumab in early/mild Alzheimer's disease, with topline data expected in Q1 2027. This is the company's largest indication by potential market size, and the trial tests foralumab both alone and alongside approved anti-amyloid drugs lecanemab and donanemab, which could position it as a complementary therapy. The readout is still roughly two quarters away, so the near-term stock impact is limited to de-risking the timeline rather than a data event. It follows a steady run of pipeline milestones — the MSA PET imaging results in July, the INFORM-MS last-visit completion in September, the first ALS patients dosed in late September, and the Orphan Drug filing for MSA on September 30 — and comes after CEO Ivor Elrifi bought roughly $986,000 of stock at $1.00 in August, well above today's $1.07 price only marginally.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 31.7% of the 1731 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TLSA was trading at $1.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $134.7M. The 52-week trading range was $0.76 to $2.20. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.